Unicancer
Valerie Ralibera is a professional with 13 years of experience in the pharmaceutical industry, specializing in pharmacovigilance. Currently serving as Chargée de données en Pharmacovigilance at AIXIAL since June 2021 and as Chargée en Pharmacovigilance at Unicancer since November 2020, Valerie handles data registration, reconciliation, and drafting safety reports. Previously, Valerie worked as a Contractor Global Safety Senior Associate at Amgen, focusing on case reporting and training new employees on the Argus database. Additional roles include serving as a Drug Safety Scientist for Servier and Pierre Fabre, with responsibilities in data recording and training. Valerie holds a Bachelor's degree in Pharmaceutical Data Management with a specialization in Pharmacovigilance from Conservatoire National des Arts et Métiers.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries